Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis.
10.1007/s11684-018-0659-3
- Author:
Xin WU
1
;
Xiaobao SHENG
2
;
Rong SHENG
1
;
Hongjuan LU
1
;
Huji XU
3
Author Information
1. Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, the Second Military Medical University, Shanghai, 200003, China.
2. School of Economics and Management, Tongji University, Shanghai, 200092, China.
3. Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, the Second Military Medical University, Shanghai, 200003, China. xuhuji@smmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
clinical markers;
gene;
rheumatoid arthritis;
therapy
- From:
Frontiers of Medicine
2019;13(4):411-419
- CountryChina
- Language:English
-
Abstract:
Although many drugs and therapeutic strategies have been developed for rheumatoid arthritis (RA) treatment, numerous patients with RA fail to respond to currently available agents. In this review, we provide an overview of the complexity of this autoimmune disease by showing the rapidly increasing number of genes associated with RA.We then systematically review various factors that have a predictive value (predictors) for the response to different drugs in RA treatment, especially recent advances. These predictors include but are certainly not limited to genetic variations, clinical factors, and demographic factors. However, no clinical application is currently available. This review also describes the challenges in treating patients with RA and the need for personalized medicine. At the end of this review, we discuss possible strategies to enhance the prediction of drug responsiveness in patients with RA.
